Lung cancer represents one of the most biologically complex and heterogeneous solid tumors, characterized by extensive genetic diversity, dynamic tumor–microenvironment interactions, and strong selective pressure from therapy.
Beyond its clinical burden, lung cancer has become a major model for studying oncogenic signaling, clonal evolution, immune escape, and lineage plasticity. Advances in genomic profiling and functional genomics have transformed lung cancer from a histologically defined disease into a collection of molecularly distinct entities with specific biological behaviors.
This article reviews current knowledge on lung cancer classification, molecular pathogenesis, tumor microenvironment, metastatic mechanisms, experimental models, and translational biomarkers from a cancer biology perspective.
Risk Factors and Molecular Determinants of Lung Tumor Initiation
Lung cancer risk arises from the interaction between environmental mutagens and intrinsic susceptibility factors that influence DNA damage accumulation and cellular repair capacity.
Major biological risk contributors include:
- Tobacco smoke exposure:
Introduces polycyclic aromatic hydrocarbons and nitrosamines that form DNA adducts, generating characteristic mutational signatures and increasing genomic instability. - Environmental and occupational carcinogens:
Asbestos, radon, heavy metals, and air pollution promote chronic inflammation and oxidative stress, facilitating mutagenesis and clonal expansion of altered epithelial cells. - Genetic susceptibility:
Variants affecting detoxification enzymes, DNA repair pathways, and inflammatory responses may modulate individual risk, although high-penetrance hereditary syndromes are rare. - Chronic lung injury and inflammation:
Conditions that disrupt epithelial homeostasis create permissive environments for malignant transformation by stimulating compensatory proliferation and altering stromal signaling.
Histological and Molecular Classification of Lung Cancer
Major Histological Types
Lung cancers are broadly classified into non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), reflecting distinct cellular origins, molecular profiles, and biological behaviors.
NSCLC (~85%) includes:
- Adenocarcinoma:
- Originates from distal airway epithelial cells and alveolar type II cells
- Frequently associated with EGFR, KRAS, ALK, and BRAF alterations
- Squamous cell carcinoma:
- Arises from proximal bronchial epithelium
- Characterized by TP53 mutations, SOX2 amplification, and frequent chromosomal instability
- Large cell carcinoma:
- Poorly differentiated tumors lacking clear glandular or squamous features
SCLC (~15%):
- High-grade neuroendocrine carcinoma
- Rapid proliferation, early dissemination, and high initial therapy sensitivity
- Almost universal inactivation of TP53 and RB1
Genomic Stratification of NSCLC
Molecular profiling has revealed that NSCLC is driven by recurrent, often mutually exclusive, oncogenic alterations:
- EGFR activating mutations (exon 19 deletions, L858R)
- ALK, ROS1, RET gene fusions
- KRAS mutations (notably G12C)
- BRAF V600E
- MET exon 14 skipping
These alterations activate receptor tyrosine kinase signaling and downstream pathways that promote cell survival and proliferation. Tumor evolution under targeted therapy often leads to secondary resistance mutations or pathway bypass mechanisms.
Molecular Subtypes of SCLC
Transcriptomic analyses classify SCLC into biologically distinct subtypes based on lineage-defining transcription factors:
- SCLC-A: ASCL1-driven neuroendocrine phenotype
- SCLC-N: NEUROD1 expression
- SCLC-P: POU2F3, associated with tuft-cell–like lineage
- SCLC-Y: YAP1, non-neuroendocrine and therapy-resistant phenotype
This classification highlights the role of lineage plasticity in tumor progression and therapeutic resistance.
Molecular Pathogenesis and Oncogenic Signaling Networks
Dysregulated Growth and Survival Pathways
Multiple oncogenic signaling pathways are constitutively activated in lung cancer:
- EGFR and other RTKs activate:
- PI3K–AKT–mTOR pathway: promotes survival and metabolism
- MAPK/ERK pathway: drives proliferation
- KRAS mutations result in persistent downstream signaling independent of receptor activation
- MET amplification and alternative RTK activation contribute to therapy escape
Crosstalk between pathways enables functional redundancy, limiting the durability of single-agent targeted therapies.
Tumor Suppressor Inactivation
Loss of tumor suppressor genes accelerates genomic instability and malignant progression:
- TP53: defective DNA damage response and apoptosis
- RB1: uncontrolled G1/S transition, especially in SCLC
- CDKN2A deletion: loss of p16-mediated cell cycle control
- STK11 (LKB1): metabolic dysregulation and immune suppression in KRAS-mutant tumors
These alterations promote tolerance to oncogenic stress and enhance evolutionary adaptability.
Epigenetic Alterations and Chromatin Remodeling
Epigenetic dysregulation contributes to transcriptional reprogramming:
- DNA hypermethylation silences tumor suppressor genes
- EZH2 overexpression enhances stemness and lineage plasticity
- Super-enhancer reorganization drives oncogene dependency
Tumor Microenvironment and Immune Landscape in Lung Cancer
Cellular Components of the Tumor Microenvironment
The lung tumor microenvironment (TME) is highly dynamic and includes:
- Cancer-associated fibroblasts (CAF):
- Promote ECM remodeling, invasion, and immune suppression
- Tumor-associated macrophages (TAM):
- M2-like macrophages enhance angiogenesis and metastasis
- Endothelial cells:
- Regulate angiogenic signaling and immune cell trafficking
Spatial organization of these components influences therapy response.
Immune Evasion Mechanisms
Lung tumors employ multiple strategies to suppress immune surveillance:
- PD-L1 upregulation via oncogenic signaling pathways
- T cell exhaustion mediated by chronic antigen exposure
- MDSC recruitment and suppressive cytokine networks (IL-10, TGF-β)
Smoking-associated tumors often display high mutational burden but paradoxically maintain immune suppression through myeloid dominance.
Inflammation and Mutagenic Microenvironments
Chronic airway inflammation promotes:
- Oxidative DNA damage
- Epigenetic remodeling
- Clonal expansion of premalignant fields
Tobacco smoke produces characteristic mutational signatures that persist long after exposure cessation.
Metastatic Progression and Cellular Plasticity
EMT and Invasion Programs
Metastasis initiation involves:
- Downregulation of epithelial junction proteins
- Activation of EMT transcription factors:
- ZEB1, SNAIL, TWIST
- Matrix metalloproteinase secretion enabling ECM degradation
EMT is often partial and reversible, contributing to hybrid phenotypes.
Circulating Tumor Cells and Metastatic Niches
CTCs exhibit:
- Increased survival via platelet cloaking
- Cluster formation enhancing metastatic efficiency
- Stem-like and immune-resistant features
Preferred metastatic sites include brain, bone, liver, and adrenal glands, each providing niche-specific growth factors.
Therapy-Induced Lineage Plasticity
Adaptive resistance may involve:
- Transformation from adenocarcinoma to SCLC phenotype
- Emergence of drug-tolerant persister cells
- Epigenetic reprogramming under drug pressure
Plasticity enables tumors to bypass pathway-specific inhibitors.
Experimental Models and Research Methodologies
In Vitro Systems
- 2D cell lines: easy manipulation but poor microenvironmental representation
- Patient-derived organoids: preserve genomic and phenotypic features
- Air–liquid interface cultures: model airway epithelial differentiation
Organoids enable drug screening and resistance modeling.
In Vivo and Ex Vivo Models
- Genetically engineered mouse models (GEMMs):
- Allow study of tumor initiation and immune interactions
- Patient-derived xenografts (PDX):
- Maintain tumor heterogeneity but lack immune components
- Precision-cut lung slices:
- Preserve native architecture and stromal elements
Each model addresses distinct biological questions.
Multi-Omics and Functional Genomics
- Single-cell RNA sequencing: reveals intratumoral heterogeneity
- Spatial transcriptomics: maps cellular neighborhoods
- CRISPR screens: identify synthetic lethal vulnerabilities
Integration of datasets supports systems-level modeling of tumor ecosystems.
Molecular Biomarkers and Translational Implications
Diagnostic and Prognostic Biomarkers
- Driver mutations define molecular subtypes
- PD-L1 expression correlates with immune phenotypes
- Gene signatures predict recurrence and survival
However, tumor heterogeneity limits single-marker reliability.
Liquid Biopsy and Evolution Tracking
Circulating tumor DNA (ctDNA) enables:
- Detection of resistance mutations
- Monitoring clonal dynamics
- Minimal residual disease detection
This approach supports real-time assessment of tumor evolution.
Target Discovery and Drug Development Strategies
Emerging approaches include:
- Synthetic lethality in KRAS-driven tumors
- Targeting lineage-specific transcriptional dependencies
- Combination regimens addressing pathway redundancy and immune suppression
Understanding adaptive resistance is essential for durable therapeutic strategies.
Lung Cancer Treatment
Lung cancer treatment has evolved from non-specific cytotoxic approaches to molecularly guided and immune-based strategies, reflecting advances in tumor biology.
From a mechanistic standpoint, treatments can be grouped into:
- Cytotoxic chemotherapy:
Targets rapidly dividing cells by inducing DNA damage or disrupting mitosis (e.g., platinum compounds, taxanes). Although effective in reducing tumor burden, it applies strong selective pressure that promotes resistant clones. - Targeted therapies:
Designed to inhibit oncogenic drivers such as EGFR, ALK, BRAF, and MET. These therapies directly suppress dominant signaling pathways but often induce adaptive resistance through secondary mutations, pathway reactivation, or phenotypic switching. - Immunotherapies:
Immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 restore anti-tumor T cell activity. Response is strongly influenced by tumor mutational burden, antigen presentation capacity, and the composition of the tumor microenvironment. - Combination strategies:
Increasingly used to overcome resistance by targeting both cancer cell–intrinsic pathways and microenvironmental factors, such as angiogenesis or immune suppression.
From a biological perspective, treatment response and resistance are best understood as evolutionary processes shaped by tumor heterogeneity and microenvironmental constraints.
Conclusion
Lung cancer exemplifies the biological complexity of solid tumors, integrating genetic diversity, epigenetic plasticity, and microenvironmental adaptation. Its progression is driven not only by oncogenic mutations but also by dynamic interactions with immune and stromal compartments. Modern lung cancer research increasingly relies on integrated multi-omics, advanced experimental models, and evolutionary frameworks to understand disease progression and therapeutic resistance. Continued investigation into spatial tumor biology, early molecular detection, and adaptive treatment strategies will be critical for advancing both fundamental cancer biology and translational applications.
